IT HAS AN INHIBITOR NAMED "ROBOTNIKININ"????
November 4, 2026 at 3:25 AM
IT HAS AN INHIBITOR NAMED "ROBOTNIKININ"????
Time for his Chornlinestrase inhibitor dose
November 4, 2026 at 1:31 AM
Time for his Chornlinestrase inhibitor dose
our noble monoamine and excitatory neurotransmission stimulant vs their vile serotonin–norepinephrine–dopamine reuptake inhibitor
November 2, 2026 at 7:22 PM
our noble monoamine and excitatory neurotransmission stimulant vs their vile serotonin–norepinephrine–dopamine reuptake inhibitor
I almost lost my daughter to H1N1. An experimental anti-viral inhibitor saved her life.
November 3, 2026 at 5:18 PM
I almost lost my daughter to H1N1. An experimental anti-viral inhibitor saved her life.
*going through my pharmacy tech lecture slides*
Paracetamol isn't a fucking AINE (NSAID) you twats it isn't a COX inhibitor jfc
Paracetamol isn't a fucking AINE (NSAID) you twats it isn't a COX inhibitor jfc
November 4, 2026 at 7:49 AM
*going through my pharmacy tech lecture slides*
Paracetamol isn't a fucking AINE (NSAID) you twats it isn't a COX inhibitor jfc
Paracetamol isn't a fucking AINE (NSAID) you twats it isn't a COX inhibitor jfc
Checkpoint inhibitor combinations: the trial-to-approval gap
www.nature.com/articles/d41...
This article analyses trends in checkpoint inhibitor clinical trials and FDA approvals, highlighting the rapid growth of combination regimens and the gap between trial activity and regulatory approvals
www.nature.com/articles/d41...
This article analyses trends in checkpoint inhibitor clinical trials and FDA approvals, highlighting the rapid growth of combination regimens and the gap between trial activity and regulatory approvals
Checkpoint inhibitor combinations: the trial-to-approval gap
Discover the world’s best science and medicine | Nature.com
www.nature.com
November 4, 2026 at 2:56 PM
Checkpoint inhibitor combinations: the trial-to-approval gap
www.nature.com/articles/d41...
This article analyses trends in checkpoint inhibitor clinical trials and FDA approvals, highlighting the rapid growth of combination regimens and the gap between trial activity and regulatory approvals
www.nature.com/articles/d41...
This article analyses trends in checkpoint inhibitor clinical trials and FDA approvals, highlighting the rapid growth of combination regimens and the gap between trial activity and regulatory approvals
More #ACR26 work from @uwrheum.bsky.social and this time it's just @nasingh.bsky.social and crew
Immune checkpoint inhibitors and inflammatory arthritis - acrabstracts.org/abstract/lon...
Immune checkpoint inhibitors and inflammatory arthritis - acrabstracts.org/abstract/lon...
Longer Immune Checkpoint Inhibitor Exposure and Greater Joint Burden Predict Persistent Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis - ACR Meeting Abstracts
Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) frequently persists after ICI cessation. However, the time course of resolution and predictors of ongoing arthri...
acrabstracts.org
November 1, 2026 at 2:17 PM
More #ACR26 work from @uwrheum.bsky.social and this time it's just @nasingh.bsky.social and crew
Immune checkpoint inhibitors and inflammatory arthritis - acrabstracts.org/abstract/lon...
Immune checkpoint inhibitors and inflammatory arthritis - acrabstracts.org/abstract/lon...
Also medication update if anyone wants one:
we doing p good chat. More chill. Lil more focused. I'm on bupropion which unlike a normal SSRI this is an NDRI (norepinephrine-dopamine reuptake inhibitor). I've been on it off and on for years and I personally love it. Just need a higher dose atm lol
we doing p good chat. More chill. Lil more focused. I'm on bupropion which unlike a normal SSRI this is an NDRI (norepinephrine-dopamine reuptake inhibitor). I've been on it off and on for years and I personally love it. Just need a higher dose atm lol
November 3, 2026 at 7:19 AM
Also medication update if anyone wants one:
we doing p good chat. More chill. Lil more focused. I'm on bupropion which unlike a normal SSRI this is an NDRI (norepinephrine-dopamine reuptake inhibitor). I've been on it off and on for years and I personally love it. Just need a higher dose atm lol
we doing p good chat. More chill. Lil more focused. I'm on bupropion which unlike a normal SSRI this is an NDRI (norepinephrine-dopamine reuptake inhibitor). I've been on it off and on for years and I personally love it. Just need a higher dose atm lol
Great fit. Amazing even. Just don’t go inventing a universal inhibitor buddy. 😉
November 1, 2026 at 10:02 PM
Great fit. Amazing even. Just don’t go inventing a universal inhibitor buddy. 😉
It just is a dopamine reuptake inhibitor. I’m prescribed 1 of those. It is not a high. Plus caffeine that’s like kicking you when you’re down lmao
November 3, 2026 at 5:35 PM
It just is a dopamine reuptake inhibitor. I’m prescribed 1 of those. It is not a high. Plus caffeine that’s like kicking you when you’re down lmao
Accountability check: at the Black Eagle when I was Spidey on Halloween, I went up to a bunch of X-Men cosplayers and apologized to them for inventing the inhibitor suppressor. They said it's all good and I urged them to go crazy and have fun all night and we did ❤️
November 1, 2026 at 10:11 PM
Accountability check: at the Black Eagle when I was Spidey on Halloween, I went up to a bunch of X-Men cosplayers and apologized to them for inventing the inhibitor suppressor. They said it's all good and I urged them to go crazy and have fun all night and we did ❤️
DNA2 is an emerging anti-cancer target. Here, we describe a workflow for DNA2 inhibitor discovery and highlight that currently used commercial DNA2i have an off-target effect on DNA synthesis, while we find no evidence of effective DNA2 inhibition in cells. authors.elsevier.com/a/1o1pR5aisD...
November 2, 2026 at 2:44 PM
DNA2 is an emerging anti-cancer target. Here, we describe a workflow for DNA2 inhibitor discovery and highlight that currently used commercial DNA2i have an off-target effect on DNA synthesis, while we find no evidence of effective DNA2 inhibition in cells. authors.elsevier.com/a/1o1pR5aisD...
inhibitor chip... active and overclocked_
sense of self... muted_
sense of self... muted_
October 29, 2026 at 3:44 AM
inhibitor chip... active and overclocked_
sense of self... muted_
sense of self... muted_
From #ESMO2026 - The next-generation KRAS G12C inhibitor divarasib represents a new standard of care for previously treated, advanced KRAS G12C-mutated #NSCLC.
Full story 👉️ buff.ly/auPWZz2
#MedNews
Full story 👉️ buff.ly/auPWZz2
#MedNews
Divarasib outplays first-generation KRAS inhibitors in advanced NSCLC
The next-generation KRAS G12C inhibitor divarasib represents a new standard of care for previously treated, advanced KRAS G12C-mutated NSCLC.
www.springermedicine.com
November 3, 2026 at 9:02 AM
From #ESMO2026 - The next-generation KRAS G12C inhibitor divarasib represents a new standard of care for previously treated, advanced KRAS G12C-mutated #NSCLC.
Full story 👉️ buff.ly/auPWZz2
#MedNews
Full story 👉️ buff.ly/auPWZz2
#MedNews
On JHI's November issue cover (rupress.org/jhi/issue/2/6): Circos plots reveal reduced predicted inflammatory cross-talk from #monocytes to other peripheral blood mononuclear cells during JAK-inhibitor treatment in two #STAT1 gain-of-function patients. Iglesias-Herrero et al. doi.org/10.70962/jhi...
November 2, 2026 at 3:06 PM
On JHI's November issue cover (rupress.org/jhi/issue/2/6): Circos plots reveal reduced predicted inflammatory cross-talk from #monocytes to other peripheral blood mononuclear cells during JAK-inhibitor treatment in two #STAT1 gain-of-function patients. Iglesias-Herrero et al. doi.org/10.70962/jhi...
Depositing a kudo for my inhibitor reread here
October 30, 2026 at 4:51 PM
Depositing a kudo for my inhibitor reread here
Thx. An inhibitor would require repeat dosing, and presumably significant cost. A vaccine could potentially be one and done.
November 1, 2026 at 2:31 AM
Thx. An inhibitor would require repeat dosing, and presumably significant cost. A vaccine could potentially be one and done.
Haha. Got the post-chemo steroids and PARP inhibitor “you look well” face.
October 31, 2026 at 9:43 AM
Haha. Got the post-chemo steroids and PARP inhibitor “you look well” face.
HHV-6 may contribute to increased IL-6 signaling and inflammation. Actemra (tocilizumab), an IL-6 receptor inhibitor, could potentially provide symptom relief by blocking this inflammatory pathway, although its effectiveness in Long COVID remains unproven.
November 2, 2026 at 4:29 AM
HHV-6 may contribute to increased IL-6 signaling and inflammation. Actemra (tocilizumab), an IL-6 receptor inhibitor, could potentially provide symptom relief by blocking this inflammatory pathway, although its effectiveness in Long COVID remains unproven.
lol there is a a PARP inhibitor in Oncology
October 29, 2026 at 5:14 PM
lol there is a a PARP inhibitor in Oncology
MEK Inhibitor Therapy for Neurofibromatosis Type 1 (NF1): Your Complete Day 1 Readiness Guide - Everyday Health
MEK Inhibitor Therapy for Neurofibromatosis Type 1 (NF1): Your Complete Day 1 Readiness Guide - Everyday Health
News update via NF Bot
news.google.com
November 4, 2026 at 11:40 AM
MEK Inhibitor Therapy for Neurofibromatosis Type 1 (NF1): Your Complete Day 1 Readiness Guide - Everyday Health
How Innovation in BTK Inhibitor Development Is Improving Treatment Outcomes. BTK inhibitors have become an important treatment option for certain B-cell malignancies. [Sponsored by BRUKINSA]
medcitynews.com/2026/11/how-...
medcitynews.com/2026/11/how-...
How Innovation in BTK Inhibitor Development Is Improving Treatment Outcomes - MedCity News
BTK inhibitor has become an important treatment option for certain B-cell malignancies.
medcitynews.com
November 2, 2026 at 3:56 PM
How Innovation in BTK Inhibitor Development Is Improving Treatment Outcomes. BTK inhibitors have become an important treatment option for certain B-cell malignancies. [Sponsored by BRUKINSA]
medcitynews.com/2026/11/how-...
medcitynews.com/2026/11/how-...
MEK Inhibitor Therapy for Neurofibromatosis Type 1 (NF1): Your Complete Day 1 Readiness Guide - Yahoo Health
MEK Inhibitor Therapy for Neurofibromatosis Type 1 (NF1): Your Complete Day 1 Readiness Guide - Yahoo Health
News update via NF Bot
news.google.com
November 3, 2026 at 11:40 AM
MEK Inhibitor Therapy for Neurofibromatosis Type 1 (NF1): Your Complete Day 1 Readiness Guide - Yahoo Health
The newly approved Phase II/III trial combines SIGX1094 with Innovent’s KRAS-G12C inhibitor fulzerasib in KRAS-G12C-mutant non-small cell lung cancer, including previously untreated patients and an exploratory cohort with resistance to prior KRAS-G12C inhibitor treatment.
November 4, 2026 at 4:18 PM
The newly approved Phase II/III trial combines SIGX1094 with Innovent’s KRAS-G12C inhibitor fulzerasib in KRAS-G12C-mutant non-small cell lung cancer, including previously untreated patients and an exploratory cohort with resistance to prior KRAS-G12C inhibitor treatment.